Medtronic surges on strong Q3 results as cardiovascular growth hits decade high
Medical device maker beats earnings estimates with 11% cardiovascular growth driven by pulsed field ablation technology
Medtronic reported its strongest quarterly revenue growth in ten years, driven by an 11% surge in its cardiovascular business and explosive demand for a new heart treatment technology that is reshaping the medical devices landscape.
The Dublin-based medical device maker delivered third-quarter fiscal 2026 earnings that beat analyst expectations, with adjusted earnings per share of $1.36 compared to estimates of $1.33. Revenue reached $9.02 billion, exceeding the $8.89 billion consensus forecast, while organic revenue grew 6%—50 basis points ahead of the company's own guidance.
The standout performance came from the cardiovascular portfolio, which grew 10.6% organically to $3.46 billion. Within that segment, Cardiac Ablation Solutions surged 80% year-over-year, including a 137% jump in the U.S. market, fueled by demand for the company's pulsed field ablation (PFA) technology. The non-thermal approach to treating irregular heartbeats is rapidly becoming the preferred method for electrophysiologists due to its safety profile and procedural efficiency.
"We delivered our highest enterprise revenue growth in 10 quarters," Medtronic executives stated in the earnings release, highlighting the company's momentum across its four operating segments. The Neuroscience portfolio grew 2.5% to $2.56 billion, Medical Surgical increased 2.7% to $2.17 billion, and the Diabetes business posted 8.3% organic growth to $796 million.
The strong quarterly performance was supported by recent regulatory wins. In February, Medtronic received FDA clearance for the Stealth AXiS surgical system, a next-generation platform that combines planning, navigation, and robotics for spine surgery. The system's real-time visualization technology aims to reduce the need for repeated imaging during procedures. The company also secured FDA clearance for its Hugo robotic-assisted surgery system in December, positioning it to compete in the soft-tissue robotics market.
Medtronic reaffirmed its full-year fiscal 2026 guidance, calling for approximately 5.5% organic revenue growth and adjusted earnings per share of $5.62 to $5.66. The guidance incorporates approximately $185 million in potential tariff impacts. Operating margins compressed to 24.1% from 26.2% a year earlier, which management attributed to increased research and development investment in growth areas like pulsed field ablation and robotics.
Analysts have grown increasingly bullish on Medtronic's prospects as the company's product pipeline accelerates. Needham upgraded the stock to "Buy" with a $121 price target in early February, arguing that Medtronic is in the early stages of launching major products in multi-billion dollar markets that should add more than 1% to organic revenue growth. Barclays reinstated coverage with an "Overweight" rating and $116 target, citing robust heart rhythm device growth and momentum in newer therapies.
The company also executed two strategic acquisitions during the quarter: CathWorks in coronary and renal denervation, and Anteris in structural heart. These deals expand Medtronic's presence in high-growth cardiovascular niches and complement its existing product portfolio.
Medtronic shares closed at $99.49 on Tuesday, giving the company a market capitalization of approximately $127.6 billion. The stock has recovered from its 52-week low of $77.73 but remains below its 52-week high of $105.55 set earlier in the year. With 30 analysts covering the stock, the consensus rating remains positive, with 16 recommending "buy" or "strong buy" and 14 advising "hold," according to market data.